Astria Therapeutics

Astria Therapeutics, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is STAR-0215, which is intended to treat Hereditary Angioedema, a rare genetic disorder characterized by severe, recurrent, unpredictable, painful, and sometimes life-threatening swelling in the face, limbs, abdomen, and airway. The company was founded by Michael R. Jirousek, Jill C. Milne and Steven E. Shoelson on June 26, 2008 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Astria Therapeutics advances STAR-0215 for HAE treatment market growth

Astria Therapeutics is making strides in developing STAR-0215 as a promising HAE preventative treatment.
Financially stable with recent stock offering, the company is focused on patient-centric innovation.
Challenges in patient enrollment and injection site reactions are being addressed proactively.
Opportunities lie in expanding clinical trials, optimizing dosing strategies, and achieving market approval.

Astria Therapeutics reports strong Q3 performance and eyes global expansion

Astria Therapeutics showcased promising data for STAR-0215 and introduced STAR-310 as potential game-changers in the therapeutic landscape.
Financially, the company is well-positioned with substantial cash reserves and secured funding for future operations, indicating stability and growth potential.
While facing challenges in trial logistics and global expansion, Astria Therapeutics has opportunities to establish market leadership in HAE and atopic dermatitis treatments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a virtual fireside chat at the upcoming H.C. Wainwright 1st Annual Hereditary Angioedema Conference on Wednesday, July 20, at 12:30pm ET. A webcast of the event can be accesse

Astria Therapeutics to Participate in Virtual Fireside Chat at Upcoming H.C. Wainwright 1st Annual Hereditary Angioedema Conference

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, presented new preclinical data that demonstrate STAR-0215's rapid and durable inhibition of plasma kallikrein in cynomolgus monkeys, supporting the potential for once every three month or longer dosing in humans. The Flash Talks session entitled “STAR-0215, a Lon

Astria Therapeutics Presents New Preclinical Data Showing Differentiated Profile of STAR-0215, in Development for Treatment of Hereditary Angioedema

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that it will share new preclinical data for STAR-0215 in two presentations at the European Academy of Allergy and Clinical Immunology (EAACI) 2022 Hybrid Congress which takes place from July 1-3, 2022 in Prague, Czech Republic. Pradeep Bista, Ph.D

Astria Therapeutics to Present New Preclinical STAR-0215 Data at the European Academy of Allergy and Clinical Immunology 2022 Hybrid Congress

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today reported financial results for the first quarter ended March 31, 2022 and provided a corporate update. “We are looking forward to advancing STAR-0215 into the clinic this year with the Phase 1a trial, which we plan to initiate shortly after our antici

Astria Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq: ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that it will share new preclinical data for STAR-0215 in a presentation titled “Development of STAR-0215: An Engineered IgG1 Monoclonal Antibody Targeting Plasma Kallikrein for the Prevention of HAE” at the 2022 Fc Receptor

Astria Therapeutics to Present STAR-0215 Data at the 2022 Fc Receptor and IgG Targeted Therapies Conference

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a corporate update. “We are excited to advance STAR-0215 to the clinic this year with the planned initiation of our Phase 1a study,” said Jill C. Miln

Astria Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE), today announced that it will share new preclinical data for STAR-0215 in a presentation titled “STAR-0215 Is a Long-Acting Monoclonal Antibody Plasma Kallikrein Inhibitor in Development for Treatment of HAE” at the 2022 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting in Phoenix, Arizona. The post

Astria Therapeutics to Present STAR-0215 Data at the 2022 American Academy of Allergy, Asthma and Immunology Annual Meeting

The consensus price target hints at a 229.5% upside potential for Astria Therapeutics, Inc. (ATXS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

How Much Upside is Left in Astria Therapeutics, Inc. (ATXS)? Wall Street Analysts Think 229%

Astria Therapeutics, Inc. (ATXS) CEO Jill Milne on Q3 2021 Results - Earnings Call Transcript

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE), today reported financial results for the third quarter ended September 30, 2021 and provided a corporate update. “Our new company name, Astria, embodies our commitment to put patients first in all that we do. Astria originates from the Greek word for star, and patients are our guiding stars. Our goal is to develop the most patient-f

Astria Therapeutics Reports Third Quarter 2021 Financial Results and Provides a Corporate Update

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE), today presented new preclinical data that included demonstration of the high potency of STAR-0215 to bind to and inhibit plasma kallikrein on a site different than lanadelumab and introduction of YTE technology to extend half-life. The poster entitled “STAR-0215 is a Long-Acting Monoclonal Antibody Plasma Kallikrein Inhibitor for th

Astria Therapeutics Presents New Preclinical Data Showing the Differentiated Profile of STAR-0215, in Development to Treat Hereditary Angioedema

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE), will report third quarter 2021 financial results before the Nasdaq Global Market open on Wednesday, November 10, 2021. Jill C. Milne, Ph.D., Chief Executive Officer, will host a conference call and webcast at 8:30am ET to provide an update on corporate developments and to discuss third quarter financial results. Conference Call Dial

Astria Therapeutics to Report Third Quarter 2021 Financial Results and Recent Corporate Developments on Wednesday, November 10

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE), today announced that it will share new preclinical results for STAR-0215 in a presentation titled “STAR-0215 Is a Long-Acting Monoclonal Antibody Plasma Kallikrein Inhibitor for the Potential Treatment of HAE” at the 2021 American College of Allergy, Asthma and Immunology Annual Scientific Meeting in New Orleans, Louisiana. The post

Astria Therapeutics to Present New STAR-0215 Preclinical Results at the 2021 American College of Allergy, Asthma and Immunology Annual Scientific Meeting

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE), today presented “Burdens of Disease and Treatment in Hereditary Angioedema: Interview Insights from HAE Patients,” supporting that there is substantial need to address both HAE disease burden and treatment burden with effective therapies that have less frequent dosing. These findings were presented at the 2021 NORD Rare Diseases and

Astria Therapeutics Presents Findings on Burdens of Disease and Treatment in Hereditary Angioedema at the 2021 NORD Rare Diseases and Orphan Products Breakthrough Summit

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE), today announced it will be presenting “Burdens of Disease and Treatment in Hereditary Angioedema: Interview Insights from HAE Patients” at the 2021 NORD Rare Diseases and Orphan Products Breakthrough Summit. The poster will be available to registrants on the NORD Rare Diseases and Orphan Products Breakthrough Summit Event Platform f

Astria Therapeutics to Present Findings on Burdens of Disease and Treatment in Hereditary Angioedema at the 2021 NORD Rare Diseases and Orphan Products Breakthrough Summit

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE), today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and provide information on lead program STAR-0215 at the following upcoming virtual investor conferences: H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021. The on-demand presentation will be available a

Astria Therapeutics to Present at Upcoming Investor Conferences

News for Astria Therapeutics Stock (ATXS)